Stock Events

Stock Events

Supernus Pharmaceuticals 

€41.2
0
-€0.6-1.44% Today

Statistics

Day High
43.2
Day Low
41.2
52W High
49.2
52W Low
26.2
Volume
696
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Aug 18
€0.01
Apr 18
€0.01
Aug 17
€0.01
May 17
€0.01
Aug 16
€0.01
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

11AugExpected
Q4 2025
Q1 2026
Next
0.25
0.41
0.56
0.72
Expected EPS
0.420294575
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow S49.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.7B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing directly with Supernus in the CNS and neurology markets.
Jazz Pharmaceuticals
JAZZ
Mkt Cap12.72B
Jazz Pharmaceuticals focuses on developing and commercializing innovative pharmaceuticals, including for neurological conditions, directly competing with Supernus.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.76B
ACADIA Pharmaceuticals specializes in the development and commercialization of medicines to treat central nervous system disorders, competing in similar markets as Supernus.
Alkermes
ALKS
Mkt Cap5.69B
Alkermes plc is involved in the development and commercialization of pharmaceuticals for CNS diseases, including schizophrenia and depression, areas where Supernus also operates.
Neurocrine Biosciences
NBIX
Mkt Cap13.25B
Neurocrine Biosciences develops and markets pharmaceuticals for neurological and endocrine-related diseases and disorders, competing in the same therapeutic areas as Supernus.
AMGEN
AMGN
Mkt Cap178B
Amgen, a biotechnology giant, has a diverse portfolio that includes treatments for neurological disorders, indirectly competing with Supernus in some areas.
Biogen
BIIB
Mkt Cap27.62B
Biogen focuses on neurology, and its portfolio includes treatments for multiple sclerosis and spinal muscular atrophy, competing with Supernus in the neurology space.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie has a broad portfolio that includes CNS treatments, such as Parkinson's and Alzheimer's disease medications, making it a competitor in the neurology market.

About

Singapore Reinsurance Corporation Limited, together with its subsidiaries, operates as a general reinsurance company in Singapore, Malaysia, Greater China, and internationally. It operates through two segments, Reinsurance and Non-Reinsurance. The company primarily writes property, liability, accident, and marine classes. It also publishes magazines, books, and other publications, as well as organizes of conferences. In addition, the company provides property management and consultancy services; and computer advisory and consultancy services, as well as management services. Singapore Reinsurance Corporation Limited was founded in 1973 and is headquartered in Singapore.
Show more...
CEO
Country
Singapore
ISIN
US8684591089

Listings

STU
DE
S49.STU
F
DE
S49.F
LSE
GB
0LB2.LSE
XNAS
US
SUPN

0 Comments

Share your thoughts

FAQ

What is Supernus Pharmaceuticals stock price today?▼
The current price of S49.STU is €41.2 EUR — it has decreased by -1.44% in the past 24 hours. Watch Supernus Pharmaceuticals stock price performance more closely on the chart.
What is Supernus Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Supernus Pharmaceuticals stocks are traded under the ticker S49.STU.
Is Supernus Pharmaceuticals stock price growing?▼
S49.STU stock has risen by +3.86% compared to the previous week, the month change is a -1.83% fall, over the last year Supernus Pharmaceuticals has showed a +51.41% increase.
When is the next Supernus Pharmaceuticals earnings date?▼
Supernus Pharmaceuticals is going to release the next earnings report on August 11, 2026.
What were Supernus Pharmaceuticals earnings last quarter?▼
S49.STU earnings for the last quarter are 0.51 EUR per share, whereas the estimation was 0.25 EUR resulting in a +102.3% surprise. The estimated earnings for the next quarter are N/A EUR per share.
Does Supernus Pharmaceuticals pay dividends?▼
Yes, S49.STU dividends are paid annual. The last dividend per share was 0.01 EUR. As of today, Dividend Yield (FWD)% is 0%.
In which sector is Supernus Pharmaceuticals located?▼
Supernus Pharmaceuticals operates in the Materials sector.
When did Supernus Pharmaceuticals complete a stock split?▼
Supernus Pharmaceuticals has not had any recent stock splits.